CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 治疗要点及长期免疫治疗中的相关微生物挑战
英文原题：Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy.
查看英文原题
Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T 细胞疗法有望改善血液系统恶性肿瘤患者的结局，但血液癌症实现长期完全缓解仍面临挑战，原因包括严重危及生命的毒性、抗肿瘤疗效有限、抗原逃逸、细胞迁移受限以及肿瘤浸润不足。此外，CAR-T 细胞与宿主肿瘤微环境之间的相互作用会显著影响 CAR-T 功能。为克服这些重大障碍，需要开发新方法和策略，以制备抗肿瘤活性更强、毒性更低的 CAR-T 细胞。尽管 CAR-T 研究取得进展，微生物耐药仍是重大阻碍。本综述讨论 CAR-T 结构和不同代际的基础知识、相关挑战，以及 CAR-T 细胞疗法潜在感染风险。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapy has shown potential in improving outcomes for individuals with hematological malignancies.
However, achieving long-term full remission for blood cancer remains challenging due to severe life-threatening toxicities such as limited anti-tumor efficacy, antigen escape, trafficking restrictions, and limited tumor invasion.
Furthermore, the interactions between CAR-T cells and their host tumor microenvironments have a significant impact on CAR-T function. To overcome these considerable hurdles, fresh methodologies and approaches are needed to produce more powerful CAR-T cells with greater anti-tumor activity and less toxicity. Despite advances in CAR-T research, microbial resistance remains a significant obstacle. In this review, we discuss and describe the basics of CAR-T structures, generations, challenges, and potential risks of infections in CAR-T cell therapy.
论文信息
- 作者
- Kalim M、Jing R、Li X、Jiang Z、Zheng N、Wang Z、Wei G、Lu Y
- 单位
- Houston Methodist Cancer Center/Weill Cornell Medicine, Houston, TX 77030, USA.United States
- 期刊
- Journal of cellular immunology2024
- 原文标识
- PubMed 38883270 · DOI 10.33696/immunology.6.189
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →